Obesity

Latest News
April 29th 2025

Access to Semaglutide, Tirzepatide for Obesity Not Equal for All

April 25th 2025

Can Medicare Sustain Widespread Access to GLP-1 Therapies?

April 22nd 2025

Unhealthy Sleep Patterns, Duration Linked With Obesity

April 14th 2025

Tirzepatide Surges, Overtakes Older Drugs in Diabetes, Obesity Care

April 12th 2025

Identifying Binge Eating Triggers Among Adults With Food Insecurity

Video Interviews
View All
April 22nd 2025

Discussing Tirzepatide’s Rise in Diabetes, Obesity Care: Jaime Almandoz, MD, MBA

August 2nd 2024

GLP-1 Agonists and the Gut-Brain Axis: A New Era in Obesity Management

January 17th 2024

Dr Ian Neeland Explores Semaglutide Alternatives and Strategies in Cases of Nonresponse

January 15th 2024

Jeff McIntyre Raises NASH Awareness Among Health Care Community

January 15th 2024

Dr Ian Neeland Discusses Uptick in Patients Seeking Semaglutide for Weight Loss

January 10th 2024

Dr Ian Neeland Explains Why Semaglutide Shortage Impacts Injectable and Not Oral Version

January 7th 2024

Dr Ian Neeland on Oral Semaglutide as a Backup Amid Injection Shortage

January 3rd 2024

Dr Ian Neeland Describes Patient Experience During Semaglutide Shortage

December 20th 2023

Dr Peter Katzmarzyk Addresses Social Determinants of Obesity, Proposes Collaborative Support

Podcasts
View All
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

February 11th 2025

Telemedicine’s Evolution and Expanding Access to Obesity, Specialty Care

More News

Based on the model, over 3 million MACE were projected over the following 10 years, approximately 496,000 of which could be prevented with the use of semaglutide. | Image credit: peter hansen - stock.adobe.com
April 9th 2025

Semaglutide Use Could Prevent Up to 2 Million MACE in 10 Years, Model Suggests

AJMC Contributor
Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.
Semaglutide. | Image Credit: K KStock - stock.adobe.com
March 14th 2025

Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive

Cameron Santoro
Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they are not cost-effective at their current prices, according to a new evaluation, placing economic burdens on patients with obesity in the US.
Wei-Li Shao
March 5th 2025

Contributor: How Can the US Health Care System Affordably and Fairly Expand GLP-1 Access for the Millions of People Who Need it?

Wei-Li Shao, MBA
Expanding coverage and access to glucagon-like peptide-1 (GLP-1) medication can be beneficial for all with the cooperation of multiple parties in health care.
Medicare Part D. | Image Credit: zimmytws - stock.adobe.com
February 27th 2025

Medicare Part D Spending Trends for Type 2 Diabetes Medications

Cameron Santoro
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising rates of type 2 diabetes and obesity.
AJMC
January 28th 2025

Understanding Insurance Coverage Policies for Incretin Mimetics for Weight Management

Dina H. Griauzde, MD, MSc, DABOM Eli W. Carter, MPH Lauren Oshman, MD, MPH, DABOM Jonathan Gabison, MD, DABOM Andrew Kraftson, MD A. Mark Fendrick, MD Stephen Lott, PharmD, MS
The high cost of incretin mimetics for weight management limits insurance coverage and potentiates variation in utilization management strategies to control near-term spending.
BMI | Image credit: Vitalii Vodolazskyi – stock.adobe.com
January 14th 2025

Global Experts Call for Overhaul in Obesity Diagnosis Framework

Hayden E. Klein
The Commission proposed using new measures beyond body mass index (BMI) to define when obesity is a disease.
Child standing on scale | Image Credit: Protsenko Dmitriy - stock.adobe.com
January 13th 2025

Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients

Brooke McCormick
Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
The Top 5 Institute for Value-Based Medicine Coverage of 2024
December 25th 2024

The Top 5 Institute for Value-Based Medicine Coverage of 2024

Hayden E. Klein
The top content from the Institute for Value-Based Medicine® (IVBM®) highlighted innovative approaches to improving care delivery, addressing obesity, and tackling health inequities across various disciplines.
Dr Yehuda Handelsman
December 20th 2024

Dr Yehuda Handelsman on How DCRM 2.0 Guidelines Refine CRM Disease Management

Brooke McCormick
In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.
Harith Rajagopalan, MD, PhD, cofounder and CEO of Fractyl Health
December 20th 2024

Contributor: Treating Obesity by Breaking the GLP-1 Pattern

Harith Rajagopalan, MD, PhD
GLP-1 drugs are remarkably effective at addressing obesity, cardiovascular, and metabolic conditions, but investigators continue to search for solutions that address the root cause of these disorders.
Top 5 Most-Read Obesity Articles in 2024
December 17th 2024

Top 5 Most-Read Obesity Articles in 2024

Laura Joszt, MA
The most-read obesity articles of 2024 mostly focused on insurance coverage of weight loss medications and costs.
Obesity | Image credit: BillionPhotos.com - stock.adobe.com
December 13th 2024

Obesity Prevalence, BMI Decreased in US for First Time in a Decade

Julia Bonavitacola
The mean body mass index (BMI) and the prevalence of obesity both dropped in 2023 for the first time in more than a decade.
Weight loss injections. | Image Credit: ricka_kinamoto - stock.adobe.com
December 5th 2024

Tirzepatide Outperforms Semaglutide in Weight Loss Trial

Cameron Santoro
Tirzepatide and semaglutide, both medications for obesity treatment, demonstrate similar safety and efficacy but tirzepatide resulted in greater levels of weight loss among patients compared with semaglutide.
Semaglutide injection | Image credit: alones - stock.adobe.com
December 5th 2024

Proposal for Medicaid, Medicare Coverage of Obesity Drugs Could Prove Difficult

Julia Bonavitacola
A proposal from the Biden administration to provide coverage of weight loss drugs through Medicaid and Medicare may cost more than it saves.
Medicare enrollment model | image credit: Vitalii Vodolazskyi - stock.adobe.com
November 26th 2024

New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Kyle Munz
If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs starting in 2026.
GLP1 injector pen | Image Credit: © alones-srock.adobe.com
November 25th 2024

FDA Advised to Update Labels on GLP-1 Weight-Loss Drugs

Maggie L. Shaw
In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight loss, with their safety and efficacy primary outcomes of interest.
Semaglutide injectors. | Image Credit :Andreas Prott- stock.adobe.com
November 21st 2024

Semaglutide Eligibility Expands to Over Half of US Adults

Cameron Santoro
Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Obesity | Image credit: MP Studio – stock.adobe.com
November 18th 2024

Overweight, Obesity to Affect 64% of Americans by 2050

Hayden E. Klein
Forecasts indicate a drastic increase in US obesity rates in the next 25 years, emphasizing the need for comprehensive public health strategies.
Vitamin D | Image Credit: © Pixelbliss-stock.adobe.com
November 12th 2024

High-Dose Vitamin D Shows Limited Added Benefits in Hypertension

Maggie L. Shaw
Two doses of vitamin D were investigated for their potential to have a positive impact on systolic and diastolic blood pressures when administered in conjunction with calcium.
Semaglutide Ozempic injection blood sugar obesity - myskin - stock.adobe.com.jpeg
November 6th 2024

Semaglutide Linked to Reduced Health Care Expenses for Patients With Obesity, HF, ASCVD

Giuliana Grossi
Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began semaglutide treatment.
Female adult using a smartphone | Image Credit: Farknot Architect - stock.adobe.com
November 4th 2024

Digital Intervention Reduces Early Childhood Obesity Risk in Diverse Populations

Brooke McCormick
Combining a digital intervention with health behavior counseling improved weight trajectories and lowered obesity risk in racially and ethnically diverse children over 24 months.
Medicaid Budget | Image Credit: zimmytws - stock.adobe.com
October 24th 2024

Medicaid Budget Survey Highlights Postpandemic Challenges and Priorities

Cameron Santoro
The Medicaid budget survey for fiscal years 2024 and 2025 revealed state predictions are expecting a decline in Medicaid enrollment and an increase in spending next year due to the end of pandemic-era policies and federal funding.
Childhood obesity | Image credit: Protsenko Dmitriy - stock.adobe.com
October 24th 2024

How to Address, Prevent Childhood Obesity in the US

Julia Bonavitacola
Establishing habits in children can help to prevent childhood obesity, a rising problem in the US.
Robert Lustig, MD, MSL
October 23rd 2024

How Sugar, Ultraprocessed Foods Are Shaping the Health of America's Youth

Hayden E. Klein
Robert Lustig, MD, MSL, warns that sugary baby foods, rising birth weights, and ultraprocessed school meals are fueling long-term health risks in children.
Semaglutide | Image Credit: Corona Borealis - stock.adobe.com
September 24th 2024

Semaglutide Improves Hidradenitis Suppurativa in Patients With Obesity

Cameron Santoro
Semaglutide treatment significantly improved quality of life and reduced flare-ups in patients with obesity and hidradenitis suppurativa.
Senate. | Image Credit: Corgarashu - stock.adobe.com
September 24th 2024

Semaglutide Accessibility and Affordability Addressed at Senate Committee Hearing

Cameron Santoro
The Senate HELP Committee held a hearing to address the high cost of semaglutide drugs, finding that many patients cannot afford them despite their potential benefits.
Syringe, pills, and measuring tape | Image credit: adragan – stock.adobe.com
September 20th 2024

5 Things Americans Should Know About Weight Loss Drugs

Hayden E. Klein
Weight loss drugs have gained attention as a tool to help combat obesity, but understanding how they work, who they’re for, and their potential downsides is key to making informed decisions.
Blood pressure | Image credit: CasanoWa Stutio - stock.adobe.com
September 5th 2024

Weight Loss Surgery Associated With Blood Pressure Control

Julia Bonavitacola
Patients who had weight-loss surgery were more likely to have managed their high blood pressure compared with those who used medications and modes of management.
Cleveland, OH Image credit: SeanPavonePhoto – stock.adobe.com
August 16th 2024

How Can We Improve Obesity Care in 2024 and Beyond?

Hayden E. Klein
At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care®, experts discussed efforts to implement obesity management science into practice.
Wegovy injections | Image credit: K KStock – stock.adobe.com
August 6th 2024

Rising Costs Lead Insurers to Drop Weight Loss Drug Coverage, Further Increasing Patient Burden

Hayden E. Klein
The growing list of insurers dropping coverage for costly GLP-1 weight loss drugs leaves patients to bear even higher out-of-pocket expenses while still struggling to meet their goals.
123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo